MX2023014437A - Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos. - Google Patents

Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos.

Info

Publication number
MX2023014437A
MX2023014437A MX2023014437A MX2023014437A MX2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A MX 2023014437 A MX2023014437 A MX 2023014437A
Authority
MX
Mexico
Prior art keywords
fluorinated
analogues
methods
same
tryptamine compounds
Prior art date
Application number
MX2023014437A
Other languages
English (en)
Spanish (es)
Inventor
Jason Wallach
Michael Dybek
Original Assignee
Saint Josephs Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saint Josephs Univ filed Critical Saint Josephs Univ
Publication of MX2023014437A publication Critical patent/MX2023014437A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2023014437A 2021-06-02 2022-06-02 Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos. MX2023014437A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195943P 2021-06-02 2021-06-02
US202163288313P 2021-12-10 2021-12-10
PCT/US2022/032000 WO2022256554A1 (en) 2021-06-02 2022-06-02 Fluorinated tryptamine compounds, analogues thereof, and methods using same

Publications (1)

Publication Number Publication Date
MX2023014437A true MX2023014437A (es) 2024-03-08

Family

ID=84324579

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023014437A MX2023014437A (es) 2021-06-02 2022-06-02 Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos.

Country Status (11)

Country Link
US (1) US20240286998A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347559A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523822A (cg-RX-API-DMAC7.html)
KR (1) KR20240017363A (cg-RX-API-DMAC7.html)
AU (1) AU2022287013A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220850A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023018652A2 (cg-RX-API-DMAC7.html)
IL (1) IL308944A (cg-RX-API-DMAC7.html)
MX (1) MX2023014437A (cg-RX-API-DMAC7.html)
WO (1) WO2022256554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US12157722B1 (en) * 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848706B1 (en) * 1995-06-06 2003-02-05 Schering Corporation Substituted benzene-fused heterocyclics as neurokinin antagonists
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
US6800637B2 (en) * 2002-09-12 2004-10-05 Wyeth Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
JP7273731B2 (ja) * 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
WO2019222552A1 (en) * 2018-05-16 2019-11-21 University Of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
CA3192617A1 (en) * 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
US20240051978A1 (en) * 2020-12-07 2024-02-15 Mindset Pharma Inc. 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders

Also Published As

Publication number Publication date
IL308944A (en) 2024-01-01
JP2024523822A (ja) 2024-07-02
CO2023018652A2 (es) 2024-01-25
US20240286998A1 (en) 2024-08-29
EP4347559A1 (en) 2024-04-10
CA3220850A1 (en) 2022-12-08
EP4347559A4 (en) 2025-04-09
AU2022287013A1 (en) 2023-12-07
KR20240017363A (ko) 2024-02-07
WO2022256554A1 (en) 2022-12-08
BR112023025340A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
CO2023018652A2 (es) Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos
CL2020002034A1 (es) Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CL2019003800A1 (es) Métodos para tratar la enfermedad de huntington.
CO2020001220A2 (es) Compuestos, composiciones y métodos
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
MX2022005380A (es) Composiciones que comprenden colina.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CO2021008816A2 (es) Moduladores de trex1
CU24743B1 (es) Composiciones inmunogénicas contra el coronavirus
MX2016011063A (es) Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
MX2018000412A (es) Moduladores de diaciglicerol aciltransferasa 2 (dgat2).
CL2020002841A1 (es) Compuestos inhibidores de rip1 y métodos para preparar y usar los mismos
MX2022003689A (es) Metodos y composiciones para el tratamiento contra una enfermedad o trastorno.
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
MX2020013004A (es) Compuestos inhibidores del transportador de monoamina 2 (vmat2), composiciones, y metodos relacionados con los mismos.
UY38969A (es) Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
AR090642A1 (es) Metodo para elaborar una composicion con sales de aluminio
MX2017011500A (es) Combinaciones y formulaciones de dosis fijas que comprenden ácido 8-hidroxi-2,2,14,14- tetrametilpentadecanodioico (etc1002) y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
CL2025003977A1 (es) Nuevos totivirus piscícolas.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2022005354A (es) Uso de un inhibidor de la cinasa janus y un inhibidor de la telomerasa para el tratamiento de neoplasias mieloproliferativas.
MX2022000356A (es) Compuesto para tratamiento de combinacion.
CL2017000302A1 (es) Composición semioquímica inhibidora de la fijacion de copepoditos de piojos de mar
CO2020003134A2 (es) Moduladores de la expresión de enac